Accelerated bookbuild offering - Joint Bookrunner Wilson Therapeutics
WILSON THERAPEUTICS
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101 (bis-choline-tetrathiomolybdate), is in development as a novel treatment for Wilson’s Disease, a rare genetic disorder in which copper builds up in the body causing severe brain and liver related symptoms. WTX101 has been successfully evaluated in a Phase 2 clinical study and a pivotal Phase 3 study, of which the design has been approved by the FDA, will start early 2018. Wilson Therapeutics was founded in 2012 and is listed in the Mid Cap segment on Nasdaq Stockholm since 2016.TRANSACTION HIGHLIGHTS
- Placement of 2,572,024 new shares, representing 10% of Wilson’s pre-deal outstanding share capital, at an issue price of SEK 95 per share, resulting in gross proceeds of SEK 244 million
- A pre-launch market sounding exercise with existing shareholders and potential new investors resulted in substantial, high-quality anchor demand, covering a large majority of the transaction
- The accelerated book-building process generated strong demand from reputable, international and Swedish institutions and sector specialist funds, such as Oppenheimer, Polar Capital, Sphera Funds Management, Granite Point Capital Management and Handelsbanken, resulting in a multiple times covered order book
- As a result of the strong demand, existing shareholders Abingworth and MVM accepted to sell in total 1,650,000 existing shares to one of the institutional investors expressing an interest to participate at the same price as the new shares, for total proceeds of SEK 157m
- Kempen was involved in more than 75% of the final allocations with a strong focus on bringing US and UK specialist investors to the company
- Transaction proceeds are envisaged to be used to fund the currently planned clinical program, preparations for the future market launch of WTX101, evaluation of additional pre-clinical and clinical activities and exploratory work in follow-on indications
Our team
Read more on:
Transactions
No transactions found
Initial Public Offering
Sale of
to
Bencis Capital Partners
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
US public offering
US public offering
US public offering
Sale to
Block trade in Boskalis shares
Sale of Rabo Bouwfonds CIF datacenter portfolio to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Accelerated bookbuild offering
Public offer for
Fundraise
Rights issue Public offer by German listed ADLER Real Estate
for Israeli listed
Accelerated bookbuild offering
Sale of Dynamic Portfolios
Public offer by German Vonovia
Accelerated bookbuild offering
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Sale of 3 German residential portfolios by Angelo Gordon
US public offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Public offer by
for
Public takeover by German Vonovia
For Austrian Conwert
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Management participation advisory in dual-track sale process
Refinancing
Initial public offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Accelerated bookbuild and private placement
Rights issue
